02.27.14
kollaGen II-xs from Certified Nutraceuticals, Inc. was found to be safe and effective in treating joint inflammation, secondary mobility, as well as providing other beneficial effects, according to a new 60 day human clinical study.
In the trial, researchers selected 20 patients’ ages 17 years to 81 years (10 males / 10 females) with confirmed joint damage and cartilage injuries, diagnosed with imaging/scoping with low to high pain scales. The optimal dosage administered is 1500mg - 2500mg daily dietary supplement taken with citric juice on an empty stomach.
Supplementation with kollaGen II-xs produced a significant treatment response at seven days for flexibility (33.3% increase; P = 0.035) and at 60 days for general pain (91.6% reduction; P = 0.005), flexibility (68.5% increase; P = 0.004) and range of motion associated pain (76.1% reduction; P = 0.011). The substantial treatment response continued through 60 days for pain (78.8% reduction; P = 0.001). There were no adverse events reported during the study and the treatment was reported to be well tolerated by study participants.
It was concluded that kollaGen II-xs is a safe novel preparation when taken at a dosage of 500mg 4 times per day. The ingredient benefited joint inflammation and pain, flexibility, as well as supported arthritic participants (rheumatoid and osteoarthritis alike). As a result, kollaGen II-xs may be a viable treatment option for the management of joint and connective tissue disorders.
For more information: www.certifiednutra.com
In the trial, researchers selected 20 patients’ ages 17 years to 81 years (10 males / 10 females) with confirmed joint damage and cartilage injuries, diagnosed with imaging/scoping with low to high pain scales. The optimal dosage administered is 1500mg - 2500mg daily dietary supplement taken with citric juice on an empty stomach.
Supplementation with kollaGen II-xs produced a significant treatment response at seven days for flexibility (33.3% increase; P = 0.035) and at 60 days for general pain (91.6% reduction; P = 0.005), flexibility (68.5% increase; P = 0.004) and range of motion associated pain (76.1% reduction; P = 0.011). The substantial treatment response continued through 60 days for pain (78.8% reduction; P = 0.001). There were no adverse events reported during the study and the treatment was reported to be well tolerated by study participants.
It was concluded that kollaGen II-xs is a safe novel preparation when taken at a dosage of 500mg 4 times per day. The ingredient benefited joint inflammation and pain, flexibility, as well as supported arthritic participants (rheumatoid and osteoarthritis alike). As a result, kollaGen II-xs may be a viable treatment option for the management of joint and connective tissue disorders.
For more information: www.certifiednutra.com
